AU2010277438B2 - Glycopolysialylation of non-blood coagulation proteins - Google Patents

Glycopolysialylation of non-blood coagulation proteins Download PDF

Info

Publication number
AU2010277438B2
AU2010277438B2 AU2010277438A AU2010277438A AU2010277438B2 AU 2010277438 B2 AU2010277438 B2 AU 2010277438B2 AU 2010277438 A AU2010277438 A AU 2010277438A AU 2010277438 A AU2010277438 A AU 2010277438A AU 2010277438 B2 AU2010277438 B2 AU 2010277438B2
Authority
AU
Australia
Prior art keywords
psa
mpsa
aminooxy
glycoprotein
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010277438A
Other languages
English (en)
Other versions
AU2010277438A1 (en
Inventor
Archana Dwivedi
Gregory Gregoriadis
Stefan Haider
Sanjay Jain
Srijit Nath
Hanspeter Rottensteiner
Juergen Siekmann
Peter Turecek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Lipoxen Technologies Ltd
Baxalta Inc
Original Assignee
Baxalta GmbH
Lipoxen Technologies Ltd
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Lipoxen Technologies Ltd, Baxalta Inc filed Critical Baxalta GmbH
Publication of AU2010277438A1 publication Critical patent/AU2010277438A1/en
Application granted granted Critical
Publication of AU2010277438B2 publication Critical patent/AU2010277438B2/en
Priority to AU2015242970A priority Critical patent/AU2015242970B2/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED, LIPOXEN TECHNOLOGIES LIMITED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC., LIPOXEN TECHNOLOGIES LIMITED
Priority to AU2017265005A priority patent/AU2017265005A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010277438A 2009-07-27 2010-07-26 Glycopolysialylation of non-blood coagulation proteins Ceased AU2010277438B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2015242970A AU2015242970B2 (en) 2009-07-27 2015-10-13 Glycopolysialylation of non-blood coagulation proteins
AU2017265005A AU2017265005A1 (en) 2009-07-27 2017-11-21 Glycopolysialylation of non-blood coagulation proteins

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22882809P 2009-07-27 2009-07-27
US61/228,828 2009-07-27
US34713610P 2010-05-21 2010-05-21
US61/347,136 2010-05-21
PCT/GB2010/001422 WO2011012850A2 (en) 2009-07-27 2010-07-26 Glycopolysialylation of non-blood coagulation proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015242970A Division AU2015242970B2 (en) 2009-07-27 2015-10-13 Glycopolysialylation of non-blood coagulation proteins

Publications (2)

Publication Number Publication Date
AU2010277438A1 AU2010277438A1 (en) 2012-02-09
AU2010277438B2 true AU2010277438B2 (en) 2015-08-20

Family

ID=46582461

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2010277438A Ceased AU2010277438B2 (en) 2009-07-27 2010-07-26 Glycopolysialylation of non-blood coagulation proteins
AU2015242970A Ceased AU2015242970B2 (en) 2009-07-27 2015-10-13 Glycopolysialylation of non-blood coagulation proteins
AU2017265005A Abandoned AU2017265005A1 (en) 2009-07-27 2017-11-21 Glycopolysialylation of non-blood coagulation proteins

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2015242970A Ceased AU2015242970B2 (en) 2009-07-27 2015-10-13 Glycopolysialylation of non-blood coagulation proteins
AU2017265005A Abandoned AU2017265005A1 (en) 2009-07-27 2017-11-21 Glycopolysialylation of non-blood coagulation proteins

Country Status (12)

Country Link
US (1) US9795683B2 (enExample)
EP (2) EP3081233B1 (enExample)
JP (1) JP5909755B2 (enExample)
KR (1) KR101912335B1 (enExample)
CN (1) CN102573920B (enExample)
AU (3) AU2010277438B2 (enExample)
CA (1) CA2769244A1 (enExample)
ES (1) ES2590679T3 (enExample)
NZ (1) NZ597600A (enExample)
RU (1) RU2533619C2 (enExample)
SG (1) SG178051A1 (enExample)
WO (1) WO2011012850A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
AU2015275284C1 (en) * 2010-07-30 2018-04-05 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
TWI534152B (zh) * 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
PL2710375T3 (pl) 2011-05-18 2019-07-31 Baxalta GmbH Testy aktywności zależne od modyfikacji
EP3412314A1 (en) 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AU2013204754C1 (en) * 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
JP2015533152A (ja) 2012-10-15 2015-11-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 第ｖｉｉ因子コンジュゲート
CZ2014150A3 (cs) * 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Konjugáty oligomeru kyseliny hyaluronové nebo její soli, způsob jejich přípravy a použití
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
SG11201808723UA (en) 2016-04-04 2018-11-29 Shire Human Genetic Therapies Conjugated c1 esterase inhibitor and uses thereof
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CA3126476A1 (en) 2019-01-23 2020-07-30 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
CN112129946A (zh) * 2020-08-16 2020-12-25 陆修委 无糖链型惰性蛋白封闭剂的制备方法及应用
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
EP0605963A2 (en) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
WO1994019877A1 (en) * 1993-02-16 1994-09-01 Telefonaktiebolaget Lm Ericsson Arrangement for telecommunication
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
US20060019877A1 (en) * 2002-09-11 2006-01-26 Conradt Harald S Hasylated polypeptides

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS54113492A (en) 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
SE466754B (sv) 1990-09-13 1992-03-30 Berol Nobel Ab Saett att kovalent binda biopolymerer till hydrofila ytor
CA2073511A1 (en) 1990-11-14 1992-05-29 Matthew R. Callstrom Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
FI935485L (fi) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
WO1996040731A1 (en) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
PT1012259E (pt) 1997-06-04 2009-11-06 Oxford Biomedica Ltd Vector dirigido a tumor
WO1999028455A1 (de) 1997-12-03 1999-06-10 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
DE69914611T2 (de) 1998-08-28 2004-12-23 Gryphon Therapeutics, Inc., South San Francisco Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
DE19852729A1 (de) 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
EP1820516B1 (en) 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7230081B1 (en) 1999-11-12 2007-06-12 Maxygen Holdings, Ltd. Interferon gamma conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP5090605B2 (ja) 2000-05-03 2012-12-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉの皮下投与
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
AU2001258536A1 (en) 2000-05-16 2001-11-26 Lipoxen Technologies Limited Derivatisation of proteins in aqueous solution
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP2226385B1 (en) 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Human Coagulation Factor VII Variants
AU2001291653A1 (en) 2000-10-02 2002-04-15 Novo-Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ES2432967T3 (es) 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Derivados del Factor VII de coagulación
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
JP2005510229A (ja) 2001-11-28 2005-04-21 ネオーズ テクノロジーズ， インコーポレイテッド アミダーゼを用いる糖タンパク質のリモデリング
JP2005535280A (ja) 2001-11-28 2005-11-24 ネオーズ テクノロジーズ， インコーポレイテッド エンドグリカナーゼを用いる糖タンパク質のリモデリング
ES2363205T3 (es) 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
DE02020425T1 (de) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
KR101031206B1 (ko) 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
WO2005014035A2 (en) * 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP2007501870A (ja) * 2003-08-08 2007-02-01 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒドロキシアルキルデンプンとｇ−ｃｓｆの複合体
TWI356065B (en) * 2003-08-08 2012-01-11 Fresenius Kabi De Gmbh Method of producing hydroxyalkyl starch derivative
ES2294535T3 (es) * 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
EP1654290B1 (en) * 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
JP4738346B2 (ja) 2003-12-03 2011-08-03 ノヴォ ノルディスク アー／エス ＧｌｙｃｏＰＥＧ化された第ＩＸ因子
EP1694712A1 (en) * 2003-12-04 2006-08-30 University of Utah Research Foundation Modified macromolecules and methods of making and using thereof
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
WO2006020372A2 (en) 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
US20090176967A1 (en) 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
CN101039965A (zh) * 2004-08-12 2007-09-19 利普生技术有限公司 唾液酸衍生物
EP1776389B1 (en) * 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
EP1789454B1 (en) * 2004-08-12 2017-07-05 Lipoxen Technologies Limited Fractionation of charged polysaccharide
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
EP1838332A1 (en) 2005-01-06 2007-10-03 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
US8217154B2 (en) * 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090017007A1 (en) 2005-08-26 2009-01-15 Maxygen Holdings Ltd. Liquid factor vii composition
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
WO2007140282A1 (en) 2006-05-24 2007-12-06 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
PL2049692T3 (pl) 2006-07-13 2016-08-31 Serum Inst India Ltd Sposób wytwarzania poli(kwasu sialowego) o wysokiej czystości
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
JP5558106B2 (ja) 2007-01-03 2014-07-23 ノボ ノルディスク ヘルス ケア アーゲー 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
EP2162535A4 (en) 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using N-acetylglucosamine transferases
TWI569810B (zh) 2007-06-26 2017-02-11 巴克斯歐塔公司 可水解之聚合茀基甲氧基羰基－連接劑
CA2690440A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
US20100239517A1 (en) 2007-10-09 2010-09-23 Stephen Brocchini Novel conjugated proteins and peptides
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
KR20110016440A (ko) 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
US20110112029A1 (en) 2008-05-23 2011-05-12 Novo Nordisk Health Care Ag Low viscosity compositions comprising a pegylated gla-domain containing protein
EP2285412A1 (en) 2008-05-23 2011-02-23 Novo Nordisk Health Care AG Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
JP5674650B2 (ja) 2008-06-04 2015-02-25 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
EP2352515A4 (en) 2008-11-03 2012-04-25 Bayer Healthcare Llc METHOD FOR TREATING HEMOPHILIA
CA2748662A1 (en) 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
WO2010120365A2 (en) 2009-04-16 2010-10-21 Wu Nian Protein-carrier conjugates
GB0908393D0 (en) 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
EA201290069A1 (ru) 2009-07-31 2012-07-30 Байер Хелскер Ллс Модифицированные полипептиды фактора ix и их применения
DE102009028526A1 (de) 2009-08-13 2011-02-24 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Modifikation und Funktionalisierung von Sacchariden
EP2480578A4 (en) 2009-09-25 2013-04-17 Vybion Inc MODIFICATION OF POLYPEPTIDE
CN107383158A (zh) 2009-11-24 2017-11-24 诺沃—诺迪斯克保健股份有限公司 纯化聚乙二醇化蛋白质的方法
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
JP2014503495A (ja) 2010-11-15 2014-02-13 バイオジェン アイデック インコーポレイテッド 過負荷結合および溶出クロマトグラフィによる選択生成物アイソフォームの富化および濃縮
EP4169525A1 (en) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
EP0605963A2 (en) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
WO1994019877A1 (en) * 1993-02-16 1994-09-01 Telefonaktiebolaget Lm Ericsson Arrangement for telecommunication
US20060019877A1 (en) * 2002-09-11 2006-01-26 Conradt Harald S Hasylated polypeptides
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEES A et al, VACCINE, vol. 24, no. 6, 6 February 2006 (2006-02-06), pages 716-729 *

Also Published As

Publication number Publication date
EP2459226B1 (en) 2016-06-29
AU2017265005A1 (en) 2017-12-07
RU2533619C2 (ru) 2014-11-20
US20110027350A1 (en) 2011-02-03
US9795683B2 (en) 2017-10-24
NZ597600A (en) 2014-05-30
ES2590679T3 (es) 2016-11-23
WO2011012850A9 (en) 2011-05-12
WO2011012850A2 (en) 2011-02-03
AU2015242970B2 (en) 2017-10-12
JP2013500375A (ja) 2013-01-07
EP2459226A2 (en) 2012-06-06
RU2012106654A (ru) 2013-09-10
CN102573920B (zh) 2015-01-14
EP3081233B1 (en) 2020-12-23
AU2015242970A1 (en) 2015-11-05
KR20170085606A (ko) 2017-07-24
EP3081233A1 (en) 2016-10-19
SG178051A1 (en) 2012-03-29
CA2769244A1 (en) 2011-02-03
WO2011012850A3 (en) 2011-04-14
JP5909755B2 (ja) 2016-04-27
AU2010277438A1 (en) 2012-02-09
KR101912335B1 (ko) 2018-10-26
CN102573920A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
US9795683B2 (en) Glycopolysialylation of non-blood coagulation proteins
KR101759300B1 (ko) 비혈액 응고 단백질의 글리코폴리시알화
US10772968B2 (en) Glycopolysialylation of non-blood coagulation proteins
US5006333A (en) Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JP5419689B2 (ja) 顆粒球コロニー刺激因子の誘導体化
US5080891A (en) Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
AU694919B2 (en) Conjugation-stabilized polypeptide compositions
EP3505186B1 (en) Nucleophilic catalysts for oxime linkage
JP6711935B2 (ja) オキシム連結のための求核触媒
AU2018204313A1 (en) Therapeutic Proteins with Increased Half-Life and Methods of Preparing Same
HK1230101A (en) Glycopolysialylation of proteins other than blood coagulation proteins
HK1230101A1 (en) Glycopolysialylation of proteins other than blood coagulation proteins
HK1171667B (en) Glycopolysialylation of proteins other than blood coagulation proteins
US20220023430A1 (en) Glycopolysialylation of blinatumomab
HK40009331B (en) Nucleophilic catalysts for oxime linkage
EA047322B1 (ru) Способ получения модифицированного терапевтического белка (варианты)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LIPOXEN TECHNOLOGIES LIMITED; BAXALTA GMBH; BAXALT

Free format text: FORMER OWNER WAS: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.; LIPOXEN TECHNOLOGIES LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired